Tardive dyskinesia in a developmentally disabled population: Manifestation during the initial stage of a minimal effective dose program

Experimental and Clinical Psychopharmacology

Volumn 4, Issue 2, 1996, Pages 218-223

  Swanson, James M ^a   Christian, Diane L ^a   Wigal, Tim ^a   Clevenger, Walter ^a   Cavoto, Kimberley Fulbright ^a   Ackerland, Valerie ^b   Dean, Donald B ^b   Carreon, Dan ^a   Potkin, Steve ^a   Crinella, Francis M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Lauterman Development Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CLORAZEPATE; HALOPERIDOL; LOXAPINE; NEUROLEPTIC AGENT; PHENOBARBITAL; PHENYTOIN; THIORIDAZINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; RATING SCALE; TARDIVE DYSKINESIA;

EID: 19144368889     PISSN: 10641297     EISSN: None     Source Type: Journal    
DOI: 10.1037/1064-1297.4.2.218     Document Type: Article

References (19)

1. Albin, R. L., Young, A. B., & Penney, J. B. (1989). The functional anatomy of basal ganglia disorders. Trends of Neuroscience, 12, 366-375.
2. Alexander, G. E., & Crutcher, M. D. (1990). Functional architecture of basal ganglia circuits: Neural substrates of parallel processing. Trends of Neuroscience, 13, 266-271.
3. Aman, M. G., Richmond, G., Stewart, A. W., Bell, J. C., & Kissel, R. C. (1987). The Aberrant Behavior Checklist: Factor validity and the effect of subject variables in American and New Zealand facilities. American Journal of Mental Deficiency, 91, 570-578.
4. Aman, M. G., & Singh, N. N. (Eds.). (1988). Psychopharmacology of the developmental disabilities. New York: Springer-Verlag.
5. American Psychiatric Association. (1979). Tardive dyskinesia. Washington, DC: Author.
6. Barnes, T. R. (1988). Tardive dyskinesia. British Medical Journal, 296, 150-151.
7. Bobruff, A., Gardos, G., Tarsy, D., Rapkin, R. M., Cole, J. O., & Moore, P. (1981). Clonazepam and phenobarbital in tardive dyskinesia. American Journal of Psychiatry, 138, 189-193.
8. Burt, D. R., Creese, I., & Snyder, S. H. (1977). Antischizophrenic drugs: Chronic treatment elevates dopamine receptor binding in brain. Science, 196, 326-328.
9. Chouinard, G., & Jones, B. D. (1980). Neuroleptic-induced supersensitivity psychosis: Clinical and pharmacologic characteristics. American Journal of Psychiatry, 137, 16-21.
10. Corbett, J. A., Harris, R., & Robinson, R. (1975). Epilepsy. In J. Wortis (Ed.), Mental retardation and developmental disabilities (Vol. 7, pp. 79-111). New York: Brunner/Mazel.
11. Cutler, N. R., & Post, R. M. (1982). State-related cyclical dyskinesia in manic-depressive illness. Journal of Clinical Psychopharmacology, 2, 360-354.
12. Gadow, K. D., & Poling, A. G. (1988). Phannacotherapy and mental retardation. San Diego, CA: College Hall Publication.
13. Gerfen, C. R. (1992). The neostriatal mosaic: Multiple levels of compartmental organization in the basal ganglia. Annal Review of Neuroscience, 15, 285-320.
14. Jeste, D. V., & Wyatt, R. J. (1982). Understanding and treating tardive dyskinesia. New York: Guilford Press.
15. Kalachnik, J. E. (1985). Applied aspects of tardive dyskinesia monitoring: Over, under, sideways, down, backward, forward, square, and round. In K. D. Gadow (Ed.), Advances in learning and behavioral disabilities (Vol. 4, pp. 133-180). Greenwich, CT: JAI Press.
16. Rusch, J. C. (1984). Characteristics that discriminate between successful and unsuccessful drug withdrawal candidates among mentally retarded persons. Unpublished doctoral dissertation, University of Illinois at Urbana-Champaign.
17. Simpson, G. M., Pi, E. H., & Sramek, J. J. (1986). An update on tardive dyskinesia. Hospital and Community Psychiatry, 37, 362-369.
18. Winer, B. J. (1971). Statistical principles in experimental design. New York: McGraw-Hill.
19. Yassa, R. (1986). Carbamazepine in the treatment of tardive dyskinesia. American Journal of Psychiatry, 143, 1191.